文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

剂量学特征聚类揭示寡转移头颈癌SABR后局部控制概率差异:OMET II期试验质量保证分析

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.
PubMed 文献 · Radiother Oncol · 2025-12-04

该研究对OMET(GORTEC 2014-04)II期试验中69例寡转移头颈鳞癌患者的98个照射病灶进行事后分析,提取20项空间与剂量学指标并行层次聚类。结果发现三个计划质量表型,其中高瘤内剂量异质性且适形性欠佳的病灶局部控制显著更优,而更均匀适形的表型局部控制较差。

要点

  • SABR计划存在广泛患者间剂量学变异,即使按试验方案标准化。
  • 高瘤内剂量异质性且适形性欠佳的病灶局部控制显著更优。
  • 更均匀适形的表型与较差局部控制相关。

核心结论

  • 在寡转移头颈鳞癌SABR中,瘤内剂量异质性可能比严格适形性更能预测局部控制,尤其在高单次剂量方案中。

研究设计与样本

  • OMET为多中心随机II期试验,比较单纯SABR与化疗-SABR在≤3个PET确认寡转移患者中的疗效。
  • 本分析为事后分析,纳入69例患者的98个照射病灶,从DICOM文件提取20项空间与剂量学指标及常规指标。
  • 采用层次聚类识别计划质量表型,Kaplan-Meier分析评估与局部控制的关联。

主要发现

  • 尽管按试验方案标准化,剂量学参数仍存在广泛患者间变异,并观察到三个聚类。
  • 高瘤内剂量异质性且适形性欠佳的病灶聚类(N=13)与显著改善的局部控制相关。
  • 更均匀且适形的表型与较差局部控制相关(N=14)。
  • 最大聚类(N=69)无明确区分模式,局部控制居中。

临床怎么用

  • 在SABR质量保证中,可考虑超越二元专家审查,探索基于复合剂量学指标的无监督聚类表型方法。

局限性

  • 本分析为事后分析,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative radiotherapy (SABR) is increasingly used in the management of oligometastatic disease. However, variability in SABR plans raises questions about their impact on local control at SABR-treated lesions (LC). We aimed to explore whether quantitative dosimetric parameters could predict LC in head and neck squamous cell carcinoma (HNSCC) patients in the OMET (GORTEC 2014-04) trial. METHODS: OMET is a multicentre randomized phase II trial comparing SABR-alone versus chemo-SABR in patients with ≤ 3 PET-confirmed oligometastases. A post-hoc analysis of all irradiated lesions (N = 98) from 69 patients was performed. Twenty spatial and dosimetric indices, together with conventional metrics including Dmin, Dmean, Dmax, total target volume and homogeneity/conformity indices, were extracted from the DICOM files. Hierarchical clustering was used to identify phenotypes of plan quality. Kaplan-Meier analyses evaluated associations with LC. RESULTS: Wide inter-patient variability in dosimetric parameters and three clusters was observed, despite SABR standardization per trial protocol. The cluster of lesions (N = 13) with high intra-tumoral dose heterogeneity and non-optimal conformity was associated with significantly improved LC. In contrast, a more homogeneous and conformal phenotype was linked to inferior LC (N = 14). The largest cluster (N = 69) showed no clearly distinctive pattern and had intermediate LC. CONCLUSIONS: In SABR for oligometastatic HNSCC, intra-tumoral dose heterogeneity may be more predictive of LC than strict conformity, particularly in high-dose per fraction regimens. A quantitative, phenotype-based machine learning approach using unsupervised clustering of composite dosimetric metrics may be explored further within SABR quality assurance frameworks beyond binary expert review alone.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Maury P, Sayous Y, Vernerey D, et al. Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process. Radiother Oncol. 2025. PMID: 41352456. doi:10.1016/j.radonc.2025.111316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。